A sponsor of an originator biological product will have to prove it is entitled to exclusivity when it is cited as the reference product in a biosimilar application, FDA indicates in a draft guidance.
The agency specifies the types of information that sponsors of biological products need to submit to show that a product qualifies as the first licensed reference product in its